DEFA14A: Quest Diagnostics Issues Supplement to Proxy Statement to Correct Typographical Error

Quest Diagnostics released a supplement to its proxy statement to correct a typographical error regarding the number of outstanding shares.

Summary

• Quest Diagnostics has issued a supplement to its previously filed Definitive Proxy Statement related to the Annual Meeting of Stockholders to be held on May 15, 2025.
• The supplement, dated April 11, 2025, addresses a typographical error on page 69 of the Proxy Statement.
• The error concerned the number of shares of common stock outstanding on the record date.
• The correction changes the number from 11,612,391 to 111,612,391 shares.
• All other information in the Proxy Statement remains unchanged.

Sentiment

Score: 7

Explanation: The document is a neutral correction of a minor error. It doesn't indicate any underlying problems or opportunities, but it does show attention to detail.

Positives

• The company promptly addressed and corrected a typographical error in its proxy statement, demonstrating attention to detail and transparency.

Future Outlook

The document does not contain any forward-looking statements beyond the scheduled Annual Meeting.

Industry Context

This announcement is a routine correction to a proxy statement, a common occurrence in corporate governance. It doesn't significantly impact the industry context for Quest Diagnostics.

Stakeholder Impact

• The correction ensures that stockholders have accurate information regarding the number of outstanding shares, which is important for voting purposes.

Next Steps

• Stockholders should read the supplement in conjunction with the original proxy statement before voting at the Annual Meeting on May 15, 2025.

Key Dates

Keywords

Proxy Statement, Supplement, Annual Meeting, Stockholders, Shares Outstanding, Quest Diagnostics